Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | UGCG | Q16739 | 1/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314936 | 0.82 | GRM5 (0.49) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL29846879 | 0.81 | CYP1A2 (0.46) | MAPTRAB9ASMN1; SMN2GRM5CYP1A2 | |
| SCHEMBL30824609 | 0.79 | GRM5 (0.35) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31134807 | 0.76 | BCAT2 (0.65) | NPC1TP53RAB9ASMN1; SMN2GRM5 | |
| SCHEMBL16799611 | 0.73 | GRM4 (0.45) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10008345 | 0.72 | GRM5 (0.63) | GRM5CYP1A2GRM3 | |
| SCHEMBL30684899 | 0.72 | GRM5 (0.57) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL18743043 | 0.72 | GRM5 (0.57) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10314930 | 0.71 | GRM5 (0.59) | GRM5GRM3 | |
| SCHEMBL31068348 | 0.71 | NPC1 (0.65) | NPC1TP53MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853237-B2 | Naphthyridinone analogs as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | NPC1 1089/4885TP53 4792/4885MAPT 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.